Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences ( (GILD) ) has provided an update.
On October 6, 2025, Gilead Sciences announced settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. to resolve patent litigations concerning generic versions of Biktarvy®. These agreements prevent the entry of generic Biktarvy tablets in the U.S. market before April 1, 2036, securing Gilead’s market position and patent protection for this product.
The most recent analyst rating on (GILD) stock is a Buy with a $133.00 price target. To see the full list of analyst forecasts on Gilead Sciences stock, see the GILD Stock Forecast page.
Spark’s Take on GILD Stock
According to Spark, TipRanks’ AI Analyst, GILD is a Neutral.
Gilead Sciences’ overall stock score reflects strong financial performance and positive earnings call highlights, particularly in HIV and oncology segments. However, the lack of technical analysis data and moderate valuation metrics slightly temper the score.
To see Spark’s full report on GILD stock, click here.
More about Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need. The company primarily produces antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, among others.
Average Trading Volume: 6,564,094
Technical Sentiment Signal: Buy
Current Market Cap: $139.8B
For an in-depth examination of GILD stock, go to TipRanks’ Overview page.